Uncertainty around the UK’s participation in pan-European clinical trials limits opportunities for UK researchers and businesses to collaborate with their counterparts in the EU, hindering medical research and limiting patient access to the latest treatments and therapies.
43. The UK should maintain alignment with EU regulations related to clinical trials, ensuring that UK-based researchers and businesses can participate in pan-European clinical trials.